Core Viewpoint - Libang Pharmaceutical (Jiangsu) Co., Ltd. focuses on the field of nephrology and has submitted a prospectus for an IPO on the Hong Kong Stock Exchange [1] Financial Performance - The core product AP301 is designed to treat hyperphosphatemia and has completed Phase III clinical trials in China, with plans to submit a new drug application soon. Global Phase III pivotal multicenter clinical trials are ongoing in the US and China [3] - The company's financial data shows no revenue in 2023, with projected revenues of 6.525 million in 2024 and 12.11 million in the first half of 2025. However, significant losses are reported, with losses of 365 million in 2023, 335 million in 2024, and 210 million in the first half of 2025 [3] - Adjusted net losses remain high, with 328 million in 2023, 286 million in 2024, and 149 million in the first half of 2025 [3] Cash Position and Shareholder Structure - The company holds cash and cash equivalents of 171 million [4] - The shareholder base includes significant stakes from Tencent at 11.732% and Guojin at 9.6166% [4]
礼邦医药港股上市在即，股东阵容强大
Sou Hu Cai Jing·2025-11-04 14:28